Strategy
Our strategy is built around advancing the next generation of vaccines and preventive medicines by focusing on the stages where capital and expertise have the greatest impact. We combine global investment discipline with a policy-driven approach to create value for innovators, investors, and healthcare systems alike.
We combine global investment discipline with a policy-driven approach to create value for innovators, investors, and healthcare systems alike.
- Early-Stage Capital for BreakthroughsWe invest at the most critical inflection points of vaccine and preventive medicine development-pre-clinical, pre-IND, and FDA Phase I & II. By bridging the funding gap in these early stages, we enable promising science to reach clinical validation and unlock follow-on financing.
- Regulatory & Clinical AccelerationOur network of FDA advisors, CRO partners, and regulatory experts helps portfolio companies navigate early trial design, IND preparation, and Phase I/II execution. We accelerate development by combining scientific due diligence with hands-on operational support.
- Translational Science PartnershipsWe actively source opportunities from leading research institutions and universities, connecting breakthrough discoveries with entrepreneurial talent. By fostering collaborations between academia and industry, we help transform promising ideas into viable, scalable therapies.
- Middle East Value CreationA cornerstone of our strategy is ensuring that our investments also deliver regional health and economic impact:
- ·Strengthening health sovereignty by reducing dependence on imported vaccines.
- Supporting public health initiatives through alignment with national immunization and prevention strategies.
- Expanding local clinical trial capacity and regulatory recognition.
- Enabling technology transfer, talent development, and integration into the global biopharma pipeline.
More → - Global-Regional IntegrationWe act as a bridge between global biotech start-ups and regional healthcare ecosystems, ensuring that innovations are not only commercially successful but also adapted to the diverse needs of emerging and established markets.
- Long-Term Impact & SustainabilityWe measure success beyond financial returns. Our investments are guided by the principle that prevention is the most effective form of medicine - delivering outcomes that reduce healthcare costs, improve quality of life, and enhance preparedness against future health crises.
Middle East Value Creation Strategy
Our investment strategy is designed not only to support global innovation in vaccines and preventive medicine but also to advance health security and long-term resilience in the Middle East. We see our role as a bridge between breakthrough science and regional healthcare priorities, ensuring that early-stage biotechnologies bring tangible benefits to communities and policymakers across the region.
Strengthening Health Sovereignty
By enabling local access to cutting-edge vaccine and biologics platforms, we help reduce dependence on imports and support regional preparedness against infectious diseases and future pandemics.
Building Clinical Capacity
We encourage the development of regional clinical trial centers, expanding patient diversity, improving regulatory alignment, and positioning the Middle East as a credible hub for early- and mid-stage trials.
Supporting Public Health Initiatives
Our investments are aligned with national healthcare strategies across the Middle East, contributing to immunization programs, preventive care policies, and long-term cost reduction for public health systems.
Ecosystem and Talent Development
By fostering collaborations between universities, research centers, and local pharmaceutical companies, we help cultivate scientific talent, generate high-value employment, and strengthen innovation ecosystems.
Regional-Global Integration
We connect Middle Eastern stakeholders with global biopharma start-ups, ensuring the region is included in the global innovation pipeline while tailoring solutions to local needs and challenges.
Through this dual mission-financial return and regional health impact-we aim to play a meaningful role in building a more resilient, self-reliant, and innovative healthcare landscape across the Middle East.
Strengthening Health Sovereignty
By enabling local access to cutting-edge vaccine and biologics platforms, we help reduce dependence on imports and support regional preparedness against infectious diseases and future pandemics.
Building Clinical Capacity
We encourage the development of regional clinical trial centers, expanding patient diversity, improving regulatory alignment, and positioning the Middle East as a credible hub for early- and mid-stage trials.
Supporting Public Health Initiatives
Our investments are aligned with national healthcare strategies across the Middle East, contributing to immunization programs, preventive care policies, and long-term cost reduction for public health systems.
Ecosystem and Talent Development
By fostering collaborations between universities, research centers, and local pharmaceutical companies, we help cultivate scientific talent, generate high-value employment, and strengthen innovation ecosystems.
Regional-Global Integration
We connect Middle Eastern stakeholders with global biopharma start-ups, ensuring the region is included in the global innovation pipeline while tailoring solutions to local needs and challenges.
Through this dual mission-financial return and regional health impact-we aim to play a meaningful role in building a more resilient, self-reliant, and innovative healthcare landscape across the Middle East.
